<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35864146</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5438</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>European journal of human genetics : EJHG</Title><ISOAbbreviation>Eur J Hum Genet</ISOAbbreviation></Journal><ArticleTitle>The value of testing for ATXN2 intermediate repeat expansions in routine clinical practice for amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>1205</StartPage><EndPage>1207</EndPage><MedlinePgn>1205-1207</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41431-022-01146-2</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Salmon</LastName><ForeName>Kristiana</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-0013-5568</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada. Kristiana.salmon@mcgill.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada. Kristiana.salmon@mcgill.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ross</LastName><ForeName>Jay P</ForeName><Initials>JP</Initials><Identifier Source="ORCID">0000-0002-8183-2524</Identifier><AffiliationInfo><Affiliation>Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Human Genetics, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertone</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gobbo</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anoja</LastName><ForeName>Nancy</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Medical Genetics, McGill University Health Centre, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karamchandani</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dion</LastName><ForeName>Patrick A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rouleau</LastName><ForeName>Guy A</ForeName><Initials>GA</Initials><Identifier Source="ORCID">0000-0001-8403-1418</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Human Genetics, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Genge</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>FRN 159279</GrantID><Agency>CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Hum Genet</MedlineTA><NlmUniqueID>9302235</NlmUniqueID><ISSNLinking>1018-4813</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000593752">ATXN2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067698">Ataxin-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019680" MajorTopicYN="N">Trinucleotide Repeat Expansion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056726" MajorTopicYN="N">Genetic Association Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067698" MajorTopicYN="N">Ataxin-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>KS, JPR, VB, MG, NA, JK, PAD, GAR declare no competing interests. AG reports consultancies or advisory boards for Alexion, AL-S Pharma, Amylyx, Anelixis, Anexon, Apellis, Atlantic Research Group, Biogen, Calico, Cytokinetics, Eli Lilly, Ionis, Mitsubishi Tanabe Pharma, Orion Pharma, QurAlis, Roche, Sanofi, UCB, and Wave Life Sciences.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>21</Day><Hour>23</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35864146</ArticleId><ArticleId IdType="pmc">PMC9626461</ArticleId><ArticleId IdType="doi">10.1038/s41431-022-01146-2</ArticleId><ArticleId IdType="pii">10.1038/s41431-022-01146-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goutman SA, Hardiman O, Al-Chalabi A, Chio A, Savelieff MG, Kiernan MC, et al. Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. Lancet Neurol. 2022;21:465&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9513754</ArticleId><ArticleId IdType="pubmed">35334234</ArticleId></ArticleIdList></Reference><Reference><Citation>Salmon K, Kiernan MC, Kim SH, Andersen PM, Chio A, van den Berg LH, et al. The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosis. Brain. 2022;145:1207&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9129091</ArticleId><ArticleId IdType="pubmed">35020823</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden AC, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466:1069&#x2013;75. doi: 10.1038/nature09320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09320</ArticleId><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonini NM, Gitler AD. Model organisms reveal insight into human neurodegenerative disease: ataxin-2 intermediate-length polyglutamine expansions are a risk factor for ALS. J Mol Neurosci. 2011;45:676&#x2013;83. doi: 10.1007/s12031-011-9548-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-011-9548-9</ArticleId><ArticleId IdType="pmc">PMC3207127</ArticleId><ArticleId IdType="pubmed">21660502</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang MD, Gomes J, Cashman NR, Little J, Krewski D. Intermediate CAG repeat expansion in the ATXN2 gene is a unique genetic risk factor for ALS-a systematic review and meta-analysis of observational studies. PLoS ONE. 2014;9:e105534. doi: 10.1371/journal.pone.0105534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0105534</ArticleId><ArticleId IdType="pmc">PMC4141758</ArticleId><ArticleId IdType="pubmed">25148523</ArticleId></ArticleIdList></Reference><Reference><Citation>Daoud H, Belzil V, Martins S, Sabbagh M, Provencher P, Lacomblez L, et al. Association of long ATXN2 CAG repeat sizes with increased risk of amyotrophic lateral sclerosis. Arch Neurol. 2011;68:739&#x2013;42. doi: 10.1001/archneurol.2011.111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2011.111</ArticleId><ArticleId IdType="pubmed">21670397</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolzhenko E, Deshpande V, Schlesinger F, Krusche P, Petrovski R, Chen S, et al. ExpansionHunter: a sequence-graph-based tool to analyze variation in short tandem repeat regions. Bioinformatics. 2019;35:4754&#x2013;6. doi: 10.1093/bioinformatics/btz431.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btz431</ArticleId><ArticleId IdType="pmc">PMC6853681</ArticleId><ArticleId IdType="pubmed">31134279</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>